GSK plc — 13F Holdings & Portfolio

CIK 1131399 · latest 13F-HR filed 2026-11-05

GSK plc manages $497.0M in 13F-reported U.S. long-equity assets across 13 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are CRSP (29.03%), VIR (19.23%), WVE (13.58%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 1 new position and exited 1; 1 existing position rose in reported value and 9 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$497.0M

Long-equity book

Holdings
13

Distinct positions

Period
2026-09-30

Filed 2026-11-05

Q/Q Activity
+1 / −1 / ↑1 / ↓9

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 98.1%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 1 →

Top Trims

Show all 9 →

Exited Positions

Show all 1 →

GSK plc Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 CRISPR THERAPEUTICS AG CRSP H17182108 $144.3M 29.03% 2,608,419 SH
2 VIR BIOTECHNOLOGY INC VIR 92764N102 $95.6M 19.23% 8,550,954 SH
3 WAVE LIFE SCIENCES INC WVE 94352A104 $67.5M 13.58% 18,245,691 SH
4 BIONTECH SE BNTX 09075V102 $65.7M 13.22% 668,526 SH
5 IDEAYA BIOSCIENCES INC IDYA 45166A102 $51.2M 10.31% 1,333,333 SH
6 CYTOKINETICS INC CYTK 23282W605 $22.4M 4.51% 340,434 SH
7 LYELL IMMUNOPHARMA INC LYEL 55083R203 $14.8M 2.98% 1,512,659 SH
8 SPERO THERAPEUTICS INC SPRO 84833T103 $11.1M 2.24% 9,190,606 SH
9 NKARTA INC NKTX 65487U108 $8.3M 1.66% 3,150,732 SH
10 FULCRUM THERAPEUTICS INC FULC 359616109 $6.6M 1.33% 1,785,714 SH
11 BICYCLE THERAPEUTICS PLC BCYC 088786108 $5.6M 1.13% 1,529,561 SH
12 REGENXBIO INC RGNX 75901B107 $2.0M 0.41% 271,456 SH
13 CVRX INC CVRX 126638105 $1.8M 0.35% 1,007,583 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-05 $497.0M 13 0001999371-26-024635
2026-06-30 2026-08-13 $602.2M 13 0001999371-26-017873
2026-03-31 2026-05-14 $599.2M 13 0001999371-26-010742
2025-12-31 2026-02-12 $799.0M 15 0001999371-26-003198
Filer Information
Address
79 NEW OXFORD STREET
LONDON WC1A 1DG
Phone
44 20 8047 5000
Filing Manager
GSK plc
London, X0
Signatory
Victoria Whyte
Authorised Signatory for and on behalf of GSK plc